Kymera Therapeutics appoints Penny Carlson
Analysis based on 6 articles · First reported Jun 08, 2026 · Last updated Jun 08, 2026
The appointment of Penny Carlson to a key leadership role at Kymera Therapeutics is likely to be viewed positively by the market, as it strengthens the company's clinical development capabilities. The retirement of Jeremy Chadwick, while significant, is mitigated by his continued advisory role, suggesting a smooth transition for Kymera Therapeutics.
Kymera Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of Penny Carlson as Senior Vice President, Development Operations. Ms. Carlson brings over two decades of biopharmaceutical leadership experience and will oversee Kymera's global clinical development operations. This move is expected to bolster the company's efforts in advancing its pipeline through mid- and late-stage development. Concurrently, Jeremy Chadwick retired from his position as Chief Operating Officer but will continue to serve as an advisor to Kymera Therapeutics through the end of the year. Nello Mainolfi, CEO of Kymera Therapeutics, expressed excitement about Ms. Carlson's arrival and gratitude for Mr. Chadwick's contributions.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard